NEW YORK (GenomeWeb News) – Bruker said today that it has entered an agreement with Loos, France-based biotech firm ImaBiotech to distribute that company's Quantinetix software for MALDI mass spec imaging.
Quantinetix enables quantification and normalization of molecules identified via MALDI mass spec imaging. The software allows for whole-body distribution analyses in which analytes are imaged and quantified across more than 25 organs. It also offers tools for single organ and targeted applications.
MALDI imaging has recently been growing in popularity in research – particularly for detection of drugs and metabolites in tissue during drug development work – but the complexity of intact tissue can make accurate quantitation of target molecules a challenge.
"ImaBiotech's Quantinetix software has helped transform MALDI imaging into a quantitative technique," Sören-Oliver Deininger, market area manager for MALDI Imaging at Bruker, said in a statement. "With this collaboration, we are now able to directly provide our customers with the benefits of Quantinetix, enabling them to achieve true quantitative results."
Financial and other terms of the agreement were not disclosed.